l-Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling

References

• Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013;38(4):633–43.
   PubMed Web of Science ®Google Scholar
• Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013;15(6):555–64.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93.
   PubMed Web of Science ®Google Scholar
• Yoshikawa N, Shimizu N, Uehara M, Oda A, Matsumiya R, Matsubara E, et al. The effects of bolus supplementation of branched-chain amino acids on skeletal muscle mass, strength, and function in patients with rheumatic disorders during glucocorticoid treatment. Mod Rheumatol. 2017;27(3):508–17.
   PubMed Web of Science ®Google Scholar
• Gerriets VA, Rathmell JC. Metabolic pathways in T cell fate and function. Trends Immunol. 2012;33(4):168–73.
   PubMed Web of Science ®Google Scholar
• Gürcan HM, Keskin DB, Stern JNH, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9(1):10–25.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, Mimori T, Koike T, et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol. 2016;26(1):80–6.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Maeshima K, Kiyonaga Y, Torigoe M, Imada C, Hamasaki H, et al. Large-vessel involvement in granulomatosis with polyangiitis successfully treated with rituximab: a case report and literature review. Mod Rheumatol. 2015;7595:1–6.
   Google Scholar
• Torigoe M, Iwata S, Nakayamada S, Sakata K, Zhang M, Hajime M, et al. Metabolic reprogramming commits differentiation of human CD27 + IgD + B cells to plasmablasts or CD27-IgD- cells. J Immunol. 2017;199(2):425–34.
   PubMed Web of Science ®Google Scholar
• Benhamron S, Pattanayak SP, Berger M, Tirosh B. mTOR activation promotes plasma cell differentiation and bypasses XBP-1 for immunoglobulin secretion. Mol Cell Biol. 2015;35(1):153–66.
   PubMed Web of Science ®Google Scholar
• Limon JJ, So L, Jellbauer S, Chiu H, Corado J, Sykes SM, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci USA. 2014;111(47):E5076–85.
   PubMed Web of Science ®Google Scholar
• Cejka D, Hayer S, Niederreiter B, Sieghart W, Fuereder T, Zwerina J, et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum. 2010;62(8):2294–302.
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Canaud G, Mirault T, Samson M, Bruneval P, Régent A, et al. mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G. Rheumatology. 2018;57(6):1011–20.
   PubMed Web of Science ®Google Scholar
• Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016;12(3):169–82.
   PubMed Web of Science ®Google Scholar
• Rhoads JP, Major AS, Rathmell JC. Fine tuning of immunometabolism for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(5):313–20.
   PubMed Web of Science ®Google Scholar
• Yan B, Huang J, Zhang C, Hu X, Gao M, Shi A, et al. Serum metabolomic profiling in patients with systemic lupus erythematosus by GC/MS. Mod Rheumatol. 2016;26(6):914–22.
   PubMed Web of Science ®Google Scholar
• Shimobayashi M, Hall MN. Multiple amino acid sensing inputs to mTORC1. Cell Res. 2016;26(1):7–20.
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441(7092):424–30.
   PubMed Web of Science ®Google Scholar
• Drummond MJ, Glynn EL, Fry CS, Timmerman KL, Volpi E, Rasmussen BB. An increase in essential amino acid availability upregulates amino acid transporter expression in human skeletal muscle. Am J Physiol Endocrinol Metab. 2010;298(5):E1011–8.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Jutabha P, Kamai T, Endou H, Anzai N. LAT1 is a central transporter of essential amino acids in human umbilical vein endothelial cells. J Pharmacol Sci. 2014;124(4):511–3.
   PubMed Web of Science ®Google Scholar
• Sinclair LV, Rolf J, Emslie E, Shi Y-B, Taylor PM, Cantrell DA. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol. 2013;14(5):500–8.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Jutabha P, Endou H, Sagara H, Anzai N. LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells. J Immunol. 2013;191(8):4080–5.
   PubMed Web of Science ®Google Scholar
• Thwaites R, Chamberlain G, Sacre S. Emerging role of endosomal toll-like receptors in rheumatoid arthritis. Front Immunol. 2014;5:1.
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6(11):823–35.
   PubMed Web of Science ®Google Scholar
• Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci. 2009;1173(1):310–7.
   PubMedGoogle Scholar
• Wang Q, Holst J. L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res. 2015;5(4):1281–94.
   PubMed Web of Science ®Google Scholar
• Taylor PM. Role of amino acid transporters in amino acid sensing. Am J Clin Nutr. 2014;99(1):223S–30S.
   PubMed Web of Science ®Google Scholar
• Ohshima Y, Kaira K, Yamaguchi A, Oriuchi N, Tominaga H, Nagamori S, et al. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. Cancer Sci. 2016;107(10):1499–505.
   PubMed Web of Science ®Google Scholar
• Yothaisong S, Dokduang H, Anzai N, Hayashi K, Namwat N, Yongvanit P, et al. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Tumour Biol. 2017;39(3):101042831769454.
   Google Scholar
• Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, et al. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer. 2013;13(1):482.
   PubMedGoogle Scholar
• Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol. 2012;12(5):325–38.
   PubMed Web of Science ®Google Scholar
• Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity. 2015;42(4):607–12.
   PubMed Web of Science ®Google Scholar
• Cibrian D, Saiz ML, de la Fuente H, Sánchez-Díaz R, Moreno-Gonzalo O, Jorge I, et al. CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis. Nat Immunol. 2016;17(8):985–96.
   PubMed Web of Science ®Google Scholar
• Mócsai A, Kovács L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12(1):43.
   PubMedGoogle Scholar